What’s Propelling Verona Pharma Plc – American Depositary Share (NASDAQ:VRNA) After Lower Shorts Reported?

June 14, 2018 - By Kenneth Lin

The stock of Verona Pharma Plc – American Depositary Share (NASDAQ:VRNA) registered a decrease of 47.83% in short interest. VRNA’s total short interest was 1,200 shares in June as published by FINRA. Its down 47.83% from 2,300 shares, reported previously. With 4,300 shares average volume, it will take short sellers 0 days to cover their VRNA’s short positions.

The stock decreased 0.31% or $0.05 during the last trading session, reaching $16.12. About 3 shares traded. Verona Pharma plc (NASDAQ:VRNA) has risen 18.86% since June 14, 2017 and is uptrending. It has outperformed by 6.29% the S&P500.

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company has market cap of $216.81 million. The company??s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. It currently has negative earnings.

More notable recent Verona Pharma plc (NASDAQ:VRNA) news were published by: Streetinsider.com which released: “Verona Pharma PLC (VRNA) Highlights Clinical Data on RPL554 as First-in-Class Treatment for COPD” on May 21, 2018, also Nasdaq.com with their article: “Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for …” published on May 21, 2018, Seekingalpha.com published: “Translate Bio readies IPO” on June 02, 2018. More interesting news about Verona Pharma plc (NASDAQ:VRNA) were released by: Nasdaq.com and their article: “Verona Pharma to Present at Upcoming Investor Conferences” published on May 30, 2018 as well as Nasdaq.com‘s news article titled: “Verona Pharma Files Shelf Registration Statement with SEC” with publication date: May 23, 2018.

Verona Pharma plc (NASDAQ:VRNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: